Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302
01. Februar 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...